DK1713501T3 - Treatment of neurodegenerative diseases using GPR49 - Google Patents

Treatment of neurodegenerative diseases using GPR49

Info

Publication number
DK1713501T3
DK1713501T3 DK04803345T DK04803345T DK1713501T3 DK 1713501 T3 DK1713501 T3 DK 1713501T3 DK 04803345 T DK04803345 T DK 04803345T DK 04803345 T DK04803345 T DK 04803345T DK 1713501 T3 DK1713501 T3 DK 1713501T3
Authority
DK
Denmark
Prior art keywords
gpr49
secretase
interacting molecule
treatment
beta
Prior art date
Application number
DK04803345T
Other languages
Danish (da)
Inventor
Carsten Hopf
Gerard Drewes
Heinz Ruffner
Original Assignee
Cellzome Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag filed Critical Cellzome Ag
Application granted granted Critical
Publication of DK1713501T3 publication Critical patent/DK1713501T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria

Abstract

The invention relates to the use of a GPR49-interacting molecule for the preparation of a pharmaceutical composition for the treatment of a neurogenerative disease. Hereby s the GPR49-interacting molecule is preferably an inhibitor of GPR49 and particularly it has the capacity to modulate the activity of gamma-secretase and/or beta-secretase. Furthermore the invention concerns a process for identifying a gamma-secretase and/or a beta-secretase modulator, comprising the following steps: a. identifying of a GPR49-interacting molecule by determining whether a given test compound is a GPR49-interacting molecule, b. determining whether the GPR49-interacting molecule of step a) is capable of modulating gamma-secretase and/or beta-secretase activity.
DK04803345T 2004-01-29 2004-11-29 Treatment of neurodegenerative diseases using GPR49 DK1713501T3 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP04001895 2004-01-29
EP04001894 2004-01-29
EP04007447 2004-03-26
EP2004004889 2004-05-07
EP2004004891 2004-05-07
PCT/EP2004/013539 WO2005074980A1 (en) 2004-01-29 2004-11-29 Treatment of neurodegenerative diseases by the use of gpr49

Publications (1)

Publication Number Publication Date
DK1713501T3 true DK1713501T3 (en) 2008-05-26

Family

ID=38556372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04803345T DK1713501T3 (en) 2004-01-29 2004-11-29 Treatment of neurodegenerative diseases using GPR49

Country Status (11)

Country Link
US (1) US20080025969A1 (en)
EP (1) EP1713501B1 (en)
JP (1) JP2007525491A (en)
AT (1) ATE383870T1 (en)
AU (1) AU2004315111B2 (en)
CA (1) CA2554353A1 (en)
DE (1) DE602004011400T2 (en)
DK (1) DK1713501T3 (en)
ES (1) ES2300852T3 (en)
PT (1) PT1713501E (en)
WO (2) WO2005074980A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ZA200804162B (en) * 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
WO2010016766A2 (en) * 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
AU2010203356B2 (en) 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CA2804161A1 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9701676B2 (en) 2012-08-24 2017-07-11 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9908863B2 (en) 2013-01-10 2018-03-06 Merck Patent Gmbh Piperidinylcarbazoles
US9902713B2 (en) 2013-11-11 2018-02-27 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP3459944B1 (en) 2014-07-04 2021-01-06 Merck Patent GmbH Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (en) * 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
AU4589297A (en) * 1996-10-07 1998-05-05 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP1146898A1 (en) * 1999-01-22 2001-10-24 Matthew John During Vaccine-mediated treatment of neurological disorders
DE19941039A1 (en) * 1999-08-28 2001-03-01 Boehringer Ingelheim Pharma gamma-secretase in vitro test system
GB0005894D0 (en) * 2000-03-10 2000-05-03 Glaxo Group Ltd Assay
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
WO2002053737A1 (en) * 2000-12-28 2002-07-11 Asahi Kasei Kabushiki Kaisha Nf-kb activating gene
WO2002060867A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
US20050288212A1 (en) * 2002-06-26 2005-12-29 Cellzome Ag Components of the presenilin-complex
EP1380644A1 (en) * 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
US7056685B1 (en) * 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
US7189539B2 (en) * 2003-11-25 2007-03-13 Bristol-Myers Squibb Company Polynucleotide encoding a human relaxin receptor, HGPRBMY5v1

Also Published As

Publication number Publication date
AU2004315111B2 (en) 2010-03-04
US20080025969A1 (en) 2008-01-31
ES2300852T3 (en) 2008-06-16
WO2005074971A1 (en) 2005-08-18
EP1713501B1 (en) 2008-01-16
JP2007525491A (en) 2007-09-06
WO2005074980A1 (en) 2005-08-18
EP1713501A1 (en) 2006-10-25
DE602004011400T2 (en) 2009-01-22
AU2004315111A1 (en) 2005-08-18
DE602004011400D1 (en) 2008-03-06
PT1713501E (en) 2008-04-30
ATE383870T1 (en) 2008-02-15
CA2554353A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
DK1713501T3 (en) Treatment of neurodegenerative diseases using GPR49
EA201070247A1 (en) PROTEAS INHIBITORS
ATE532518T1 (en) DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES
NO20083002L (en) Method for using CD40 binding compounds
ATE506951T1 (en) TERTIARY CARBINAMINES ACTIVE AS INHIBITORS OF BETA-SECRETASE WITH SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ATE550338T1 (en) SPIROPIPERIDINE INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EA200900802A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DISEASES
NO20080318L (en) Use of single dose of CD-20-specific binding molecules
DE60329316D1 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
EA200600078A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DISEASES
ATE537152T1 (en) COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF METABOLIC DISORDERS
DK1567488T3 (en) Hydroxyethylamine derivatives for the treatment of Alzheimer's disease
DK1631295T3 (en) Use of Condensed Heterocyclic Compounds as SCCE Inhibitors in the Treatment of Skin Diseases
NO20072092L (en) sulfonamide
EA200702567A1 (en) INHIBITORS DIPEPTIDYL PEPTIDASE IV, BASED ON PYRROPYRIDINE
MA31858B1 (en) SUBSTITUTED N-PHENYL-BIPYRROLIDINE-CARBOXAMIDES AND THERAPEUTIC USE THEREOF
ATE413406T1 (en) BENZOTHIAZOLE, THIAZOLOPYRIDINE, BENZOOXAZOLE AND OXAZOLOPYRIDINE DERIVATIVES AS COMPOUNDS FOR THE TREATMENT OF DIABETES
ATE538651T1 (en) SPIROPIPERIDINE INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2006034296A3 (en) Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
DE602005027388D1 (en) MALONIC ACID AMID DERIVATIVES AS INHIBITORS OF G-SEKRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
EA200601837A1 (en) PETROXASES FOR TREATMENT OF RESPIRATORY DISEASES
NO20081727L (en) Treatment of autoimmune diseases
EE200400031A (en) A composition of biochemical compounds, its use for inhibiting matrix metalloproteinases, and a pharmaceutical formulation containing it
CY1109975T1 (en) PARA-ALKYL-SUBSTITUTED N-(4-HYDROXY-3-METHOXY-BENZYL) AMIDIA AMINAMIC ACID AND THEIR USE FOR PARASKA
DE60309719D1 (en) N-SUBSTITUTED-1H-INDOL-5-PROPANIC ACID COMPOUNDS AS PPAR AGONISTS FOR THE TREATMENT OF DIABETIS